[CLAIMS]

[Claim 1]

A drug containing a magnetic metal-salen complex compound as a medicinal component and containing a chelating agent for chelating metal of the metal-salen complex compound as a responsive component for suppressing side effects of the metal-salen complex compound, wherein the metal-salen complex compound is localized at an affected site by an external magnetic field applied from outside a body; and when the application of the external magnetic field is finished, the chelating agent binds to the metal-salen complex compound which is released from the affected site by administering the chelating agent into the body.

[Claim 2]

The drug according to claim 1, wherein the chelating agent is contained at 0.3 μM or more and 50 μM or less.

[Claim 3]

The drug according to claim 1 or 2, wherein the chelating agent is composed of the following compound.

General Name: deferasirox



[Claim 4]

The drug according to claim 1 or 2, wherein the chelating agent is composed of the following compound.

General Name: deferoxamine



[Claim 5]

The drug according to any one of claims 1 to 4, further containing vitamin C.

[Claim 6]

The drug according to any one of claims 1 to 5, wherein when the metal-salen complex compound is used as an anti-tumor agent, cytotoxicity of the metal-salen complex is neutralized by the chelating agent.

[CLAIMS]

[Claim 1]

A drug containing a magnetic iron-salen complex compound as a medicinal component and containing a chelating agent for chelating iron of the iron-salen complex compound as a responsive component for suppressing side effects of the iron-salen complex compound, wherein the iron-salen complex compound is localized at an affected site by an external magnetic field applied from outside a body; and when the application of the external magnetic field is finished, the chelating agent binds to the iron-salen complex compound which is released from the affected site by administering the chelating agent into the body

wherein the chelating agent is composed of the following compound is:

General Name: deferasirox



; or

General Name: deferoxamine



[Claim 2]

The drug according to claim 1, wherein the chelating agent is contained at 0.3 μM or more and 50 μM or less.

[Claim 3]

The drug according to claim 1 or 2, further containing vitamin C.

[Claim 4]

The drug according to any one of claims 1 to 3, wherein when the iron-salen complex compound is used as an anti-tumor agent, cytotoxicity of the iron-salen complex is neutralized by the chelating agent.